KRAS and neoplasm: However, in patients expressing wildtype BRAF and NRAS or KRAS gain-of-function mutations, B-Raf inhibitors become ineffective and tumours persist – warranting the development of novel effective treatments [10–15] http://www.sanger.ac.uk/genetics/CGP/cosmic/ [16, 17] (Fig. 4).